Metabolic Syndrome
Also known as: Insulin resistance syndrome, Metabolic syndrome X
Methodology & AI Transparency ⓘ
Metabolic Syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is metabolic syndrome? Metabolic syndrome is the name for a group of risk factors for heart disease , diabetes , and other health problems.
- 2 Real-world patient consensus: Synonyms for Metabolic Syndrome (E65.1): Insulin resistance syndrome, Metabolic syndrome X (Weight & Metabolism).
- 3 Typical cash cost range: Differential triage of Metabolic Syndrome (E65.1) utilizes hepatic steatosis screening in Metabolic Syndrome (E65.1: (FIB-4)).
- 4 Top reported side effects / signs: Objective lab/clinical target for Metabolic Syndrome: Waist-to-Height Ratio [Metabolic Syndrome E65.1] (< 0.50 (E65.1)) and HOMA-IR Insulin Resistance in Metabolic Syndrome (E65.1: Index).
Ask our AI Specialists anything about Metabolic Syndrome
What Is Metabolic Syndrome?
What is metabolic syndrome? Metabolic syndrome is the name for a group of risk factors for heart disease , diabetes , and other health problems. You can have just one risk factor, but people often have several of them together. When you have at least three of them, it is called metabolic syndrome. These risk factors include: A large waistline, also called abdominal obesity or "having an apple shape." Too much fat around the stomach is a greater risk factor for heart disease than too much fat in other parts of the body. Having a high triglyceride level. Triglycerides are a type of fat found in the blood. Having a low HDL cholesterol level .
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Metabolic Syndrome (ICD-10 E65.1) is driven by ectopic hepatic lipid in Metabolic Syndrome (E65.1: storage); Cross-referenced with NIH MeSH (Metabolic Syndrome), specialists in Weight Management & Metabolic Syndrome monitor HOMA-IR Insulin Resistance in Metabolic Syndrome (E65.1: Index) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Having a high triglyceride level. Triglycerides are a type of fat found in the blood
- • Having a low HDL cholesterol level . HDL is sometimes called the "good" cholesterol because it helps remove cholesterol from your arteries
- • Presentation of Metabolic Syndrome (E65.1): persistent hunger signaling [Metabolic Syndrome E65.1]
- • Secondary Metabolic Syndrome clinical sign: co-existing blood pressure, in Metabolic Syndrome (E65.1: triglyceride, or fasting)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Metabolic Syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E65.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Metabolic Syndrome E65.1] | < 0.50 (E65.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Metabolic Syndrome (E65.1: Index) | < 1.4 (E65.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Metabolic Syndrome (E65.1: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E65.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Metabolic Syndrome
Treatment selection for Metabolic Syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Metabolic Syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of testosterone replacement therapy for treating metabolic disturbances: What a 1,373-Participant Study Found This study demonstrated greater improvement in metabolic profiles for patients given TRT versus placebo. International urology and nephrology • 2021-09-15 • Meta-Analysis | N = 1,373 | 99/100 | PMID 34089171 ↗ |
| New Insights on Tirzepatide reduces the predicted risk of atherosclerotic heart and blood vessel: What a 2,461-Participant Study Found Tirzepatide treatment significantly reduced the 10-year predicted risk of ASCVD versus placebo in patients with obesity or overweight without diabetes. Diabetes, obesity & metabolism • 2024-01-15 • Phase III Randomized Trial | N = 2,461 | 96/100 | PMID 37932236 ↗ |
| New Insights on Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the: What a 1,145-Participant Study Found In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. JACC. Heart failure • 2025-11-15 • Randomized Controlled Trial | N = 1,145 | 96/100 | PMID 41045908 ↗ |
| New Insights on Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated: What a 1,197-Participant Study Found In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The New England journal of medicine • 2025-06-05 • Phase III Randomized Trial | N = 1,197 | 96/100 | PMID 40305708 ↗ |
| New Insights on Metabolic and heart and blood vessel effects of TX-001HR in menopausal women with: What a 1,835-Participant Study Found One episode of deep venous thrombosis and three cases of heart and blood vessel disease were observed, similar to expected rates of these events in the general population. Climacteric : the journal of the International Menopause Society • 2019-12-15 • Randomized Controlled Trial | N = 1,835 | 96/100 | PMID 31364889 ↗ |
Metabolic Syndrome Patient Community & “People Like Me” Threads
Filter Metabolic Syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.